#Canada #Vancouver #Victory Square #Insu Therapeutics #needle-free insulin

Victory Square Technologies Announces U.S. Patent Allowance for Insu Therapeutics' Innovative Delivery Platform

Victory Square Technologies Inc. has achieved a significant milestone with the announcement of a U.S. patent allowance for its portfolio company, Insu Therapeutics Inc. This patent, from the United States Patent and Trademark Office, covers Insu's revolutionary buccal peptide-delivery technology, which could redefine insulin administration for diabetes patients.

Understanding the Needle-Free Revolution

Insu Therapeutics' innovative products, namely InsuTab™, aimed at buccal insulin delivery, and BuccaGLP™, focusing on the delivery of semaglutide, represent a shift towards more convenient diabetes treatment methods. These formulations intend to deliver peptide medicines through the buccal lining of the mouth, eliminating the need for needles commonly associated with insulin injections.

According to Shafin Diamond Tejani, CEO of Victory Square, this patent allowance strengthens the foundation of Insu’s business model. It also integrates seamlessly with the exclusive global license Insu holds from the University of British Columbia (UBC). This permits the company to develop, market, and commercialize its licensed technology worldwide.

The Significance of the Patent Allowance

The newly allowed U.S. Patent Application No. 18/513,373 describes a mucoadhesive pharmaceutical dosage form tailored specifically for the buccal delivery of peptide therapeutics. This innovation is designed to adhere to the inner cheek, allowing for targeted release of the therapeutic agent directly into the underlying tissues, thus bypassing the gastrointestinal absorption path typically required when medications are swallowed.

The potential impact of such delivery methods cannot be understated, especially when considering the necessity for injections in current diabetes care. Initial data suggests that Insu’s buccal insulin and semaglutide formulations will not necessitate ‘fasting’ or strict dietary constraints that are often required with other ingested forms of peptide treatments. Such improvements in convenience could dramatically enhance patient compliance and overall treatment adherence.

Research and Development Updates

Insu Therapeutics has already initiated extensive preliminary research, successfully conducting laboratory, cell-culture, and animal studies at UBC to validate the efficacy of its buccal insulin program. The research team's findings were published in the journal Pharmaceutics. The publication detailed the rationale behind the buccal delivery approach and outlined its potential benefits.

The company believes that turning these research findings into practical, needle-free solutions could revolutionize how patients manage their diabetes. The exclusive licensing agreement with UBC serves not just as a foundational stone but also positions Insu to explore further opportunities within this expanding market.

A Growing Market in Diabetes Treatments

The global market for GLP-1 medicines, which includes semaglutide, is poised for significant growth, with estimates suggesting a surge from approximately $79 billion in sales by 2025 to about $190 billion by 2035, as reported by Morgan Stanley Research. Success in Insu's development and regulatory approval processes could potentially translate its needle-free solutions into a substantial market share.

Partnerships and Future Development

Victory Square has fostered relationships that enhance Insu's development and distribution strategy. Insu's collaboration with Hydreight Technologies, which includes a previous investment and distribution rights for peptide therapeutics using the buccal delivery system, adds an essential layer of support. This partnership connects Insu’s innovations to healthcare infrastructures across the U.S., potentially streamlining product distribution once regulatory approvals are secured.

Conclusion

Victory Square Technologies’ advancement in the pharmaceutical landscape through Insu Therapeutics' novel delivery systems signifies a critical step forward in diabetes care. As these innovations progress, they may set new standards for peptide medicine administration—making treatment safer, simpler, and more accessible for patients worldwide. The journey is far from over, but with each patent, partnership, and research milestone, Insu is paving the way for a future where diabetes management is as straightforward and needle-free as possible. InsuTab and BuccaGLP remain investigational products and are not yet available for commercial sale. The path to bringing these technologies to market will require further research, development, and regulatory approvals.